StreetInsider.com News Articles

Form EFFECT HCW Biologics Inc.

Tue, 13 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261013/27176275.html

HCW Biologics targets 1H 2027 IND filing for solid tumor therapy

Fri, 09 Oct 2026 09:02:10 -0400

HCW Biologics Inc. (NASDAQ: HCWB) said it received guidance from the U.S. Food and Drug Administration at a recent Type B meeting on steps needed to prepare an Investigational New Drug application for HCW11-018b, its lead candidate in a second-generation T-Cell Engager program, for use in treating solid tumors.

The company said the IND application remains on track to be filed in the first half of 2027. Manufacturing of current Good Manufacturing Practice material for clinical trials is underway.

HCW11-018b is built on the company's proprietary non-Fc-based TRBC platform technology. The compound combines a bispecific T-Cell Engager component with additional molecular elements,

HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors

Fri, 09 Oct 2026 09:00:00 -0400

Communication with FDA at recent Type B meeting provided clear guidance for next steps to prepare IND application to support first-in-human clinical study in cancer

HCW11-018b is Company’s lead candidate in its second-generation T-Cell Engager Program constructed using proprietary non-FC based TRBC platform technology

Manufacturing of cGMP material for clinical trials is underway

IND application remains on track to be filed in 1H 2027

MIRAMAR, Fla., Oct. 09, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on

HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors

Fri, 09 Oct 2026 09:00:00 -0400

Communication with FDA at recent Type B meeting provided clear guidance for next steps to prepare IND application to support first-in-human clinical study in cancer

HCW11-018b is Company’s lead candidate in its second-generation T-Cell Engager Program constructed using proprietary non-FC based TRBC platform technology

Manufacturing of cGMP material for clinical trials is underway

IND application remains on track to be filed in 1H 2027

MIRAMAR, Fla., Oct. 09, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on

Form D HCW Biologics Inc.

Thu, 08 Oct 2026 10:52:00 -0400

si-local-file:///var/storage/secattach/20261008/27165478.html

Form S-1 HCW Biologics Inc.

Fri, 02 Oct 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20261002/27142850.html

Form DEF 14A HCW Biologics Inc. For: Oct 01

Thu, 01 Oct 2026 10:00:00 -0400

si-local-file:///var/storage/secattach/20261001/27133189.html

Form 8-K HCW Biologics Inc. For: Sep 23

Thu, 24 Sep 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260924/27099317.html

HCW Biologics prices $1.5M private placement with existing investor

Thu, 24 Sep 2026 08:25:14 -0400

HCW Biologics Inc. (NASDAQ: HCWB) announced the pricing of a $1.5 million private placement with an existing stockholder, according to a press release issued Sept. 24, 2026.

Under a securities purchase agreement signed Sept. 23, 2026, the Miramar, Fla.-based company agreed to issue and sell 903,614 units at a combined purchase price of $1.6599 per unit. Each unit consists of one pre-funded warrant to purchase one share of common stock and the right to receive one common stock purchase warrant, subject to stockholder approval.

The pre-funded warrants carry an exercise price of $0.0001 per share, are immediately exercisable, and do not expire

HCW Biologics Announces Pricing of $1.5 Million Private Placement

Thu, 24 Sep 2026 08:25:00 -0400

MIRAMAR, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today announced the pricing of its $1.5 million private placement (the “Offering”) with an existing stockholder of the Company, (the “Investor”). Pursuant to a securities purchase agreement entered into on September 23, 2026 with the Investor (the “Purchase Agreement”), the Company agreed to issue and sell an aggregate of 903,614 units (the “Units”), with each Unit consisting of (i) one pre-funded warrant (a

HCW Biologics Announces Pricing of $1.5 Million Private Placement

Thu, 24 Sep 2026 08:25:00 -0400

Form 8-K HCW Biologics Inc. For: Sep 09

Thu, 10 Sep 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260910/27044521.html

HCW Biologics signs distribution deal with Akron Biotech for HCW11-006

Tue, 08 Sep 2026 08:50:42 -0400

HCW Biologics Inc. (NASDAQ: HCWB) announced it has entered into an exclusive distribution agreement with Akron Biotech for the commercialization of HCW11-006, a multi-cytokine fusion molecule, for use as a reagent in the production of CAR-T cells.

Under the agreement, HCW Biologics will supply research and cGMP-grade HCW11-006, while Akron Biotech will market and distribute the reagent through its network of research institutions and commercial companies. The agreement includes pre-payment commitments for product sales. Akron Biotech is a manufacturer of ancillary materials and a contract development and manufacturing organization serving the cell, gene therapy, and regenerative medicine industries.

HCW11-006 combines the effects

HCW Biologics signs distribution deal with Akron Biotech for HCW11-006

Tue, 08 Sep 2026 08:50:42 -0400

HCW11-006 combines the effects

HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells

Tue, 08 Sep 2026 08:50:00 -0400

Agreement includes pre-payment commitments for product sales and distribution of the second-generation multi-cytokine-based HCW11-006 for use as a reagent

Akron is a leading supplier of critical ancillary materials and accessory molecules for clinical and commercial scale-up of cell, gene and regenerative therapy products

HCW Biologics supplies research and cGMP-grade HCW11-006 and Akron markets and distributes the reagent to its established network of research institutions and commercial companies

Company showed in studies that CAR-T cells manufactured using HCW11-006 as a reagent exhibited strong anti-tumor activity and enhanced antiviral potency as well as potential for

HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells

Tue, 08 Sep 2026 08:50:00 -0400

Agreement includes pre-payment commitments for product sales and distribution of the second-generation multi-cytokine-based HCW11-006 for use as a reagent

Akron is a leading supplier of critical ancillary materials and accessory molecules for clinical and commercial scale-up of cell, gene and regenerative therapy products

HCW Biologics supplies research and cGMP-grade HCW11-006 and Akron markets and distributes the reagent to its established network of research institutions and commercial companies

Company showed in studies that CAR-T cells manufactured using HCW11-006 as a reagent exhibited strong anti-tumor activity and enhanced antiviral potency as well as potential for

HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment

Wed, 02 Sep 2026 09:00:00 -0400

HCW9302 is a best-in-class IL-2-based immunotherapeutic for treatment of autoimmune diseases through expanding and activating regulatory T cells

Patent allowance received for use of HCW9302 as treatment for alopecia areata

Phase 1 dose-escalating clinical study evaluating HCW9302 as monotherapy in patients with alopecia areata on track for completion in Q4 2026, continues to be well tolerated with no dose-limiting toxicities

Preliminary readout of first two dose cohorts is encouraging -- patients diagnosed with alopecia areata show positive response after single dose of monotherapy at 3 micrograms/kg dose level

MIRAMAR, Fla., Sept.

HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment

Wed, 02 Sep 2026 09:00:00 -0400

HCW9302 is a best-in-class IL-2-based immunotherapeutic for treatment of autoimmune diseases through expanding and activating regulatory T cells

Patent allowance received for use of HCW9302 as treatment for alopecia areata

Phase 1 dose-escalating clinical study evaluating HCW9302 as monotherapy in patients with alopecia areata on track for completion in Q4 2026, continues to be well tolerated with no dose-limiting toxicities

Preliminary readout of first two dose cohorts is encouraging -- patients diagnosed with alopecia areata show positive response after single dose of monotherapy at 3 micrograms/kg dose level

MIRAMAR, Fla., Sept.

Form S-1/A HCW Biologics Inc.

Fri, 28 Aug 2026 16:42:00 -0400
si-local-file:///var/storage/secattach/20260828/26998697.html

Form S-1/A HCW Biologics Inc.

Fri, 28 Aug 2026 16:42:00 -0400
si-local-file:///var/storage/secattach/20260828/26998697.html

HCW Biologics advances two cancer drug candidates using TGF-β/IL-15

Tue, 25 Aug 2026 09:02:44 -0400

HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company, has identified a TGF-β trap and IL-15 fusion as a novel moiety with potential applications against diseased cells and viral infections, according to a press release.
Human studies showed the TGF-β trap and IL-15 fusion promoted expansion of progenitor CD8+ T cells and Natural Killer cells, provided clinical benefit, and was tolerated in cancer patients. The fusion also demonstrated activity against HIV-1 and bronchopulmonary dysplasia in animal models, with data published in several scientific journals.
The company has incorporated the TGF-β/IL-15 moiety into two second-generation drug candidates developed using its TRBC drug development

HCW Biologics advances two cancer drug candidates using TGF-β/IL-15

Tue, 25 Aug 2026 09:02:44 -0400

HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company, has identified a TGF-β trap and IL-15 fusion as a novel moiety with potential applications against diseased cells and viral infections, according to a press release.
Human studies showed the TGF-β trap and IL-15 fusion promoted expansion of progenitor CD8+ T cells and Natural Killer cells, provided clinical benefit, and was tolerated in cancer patients. The fusion also demonstrated activity against HIV-1 and bronchopulmonary dysplasia in animal models, with data published in several scientific journals.
The company has incorporated the TGF-β/IL-15 moiety into two second-generation drug candidates developed using its TRBC drug development

HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells

Tue, 25 Aug 2026 09:00:00 -0400

Human studies show that the TGF-β trap and IL-15 fusion used alone promotes expansion of progenitor CD8⁺ T cells and NK cells

Company has incorporated the TGF-β/IL-15 moiety into the constructs of its second-generation fusion immunotherapeutics constructed with novel TRBC drug development platform

MIRAMAR, Fla., Aug. 25, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune diseases, cancer, and senescence-associated dysplasia, together with collaborators at leading research institutions, have identified a TGF-β trap and

HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells

Tue, 25 Aug 2026 09:00:00 -0400

Human studies show that the TGF-β trap and IL-15 fusion used alone promotes expansion of progenitor CD8⁺ T cells and NK cells

Company has incorporated the TGF-β/IL-15 moiety into the constructs of its second-generation fusion immunotherapeutics constructed with novel TRBC drug development platform

MIRAMAR, Fla., Aug. 25, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune diseases, cancer, and senescence-associated dysplasia, together with collaborators at leading research institutions, have identified a TGF-β trap and

HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells

Tue, 25 Aug 2026 09:00:00 -0400

Human studies show that the TGF-β trap and IL-15 fusion used alone promotes expansion of progenitor CD8⁺ T cells and NK cells

Company has incorporated the TGF-β/IL-15 moiety into the constructs of its second-generation fusion immunotherapeutics constructed with novel TRBC drug development platform

MIRAMAR, Fla., Aug. 25, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune diseases, cancer, and senescence-associated dysplasia, together with collaborators at leading research institutions, have identified a TGF-β trap and